Literature DB >> 19012999

Imatinib in the treatment of nephrogenic systemic fibrosis.

Sindhu Chandran1, Jeffrey Petersen, Charlotte Jacobs, David Fiorentino, Katherine Doeden, Richard A Lafayette.   

Abstract

Nephrogenic systemic fibrosis is a disabling progressive condition that is being reported with increased frequency in patients with kidney disease. Treatment is extremely limited and largely supportive. We report a case of severe nephrogenic systemic fibrosis in a dialysis patient exposed to multiple doses of gadolinium who improved clinically and histologically with treatment with imatinib.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19012999     DOI： 10.1053/j.ajkd.2008.08.029

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


  13 in total

Review 1.  Tyrosine kinases in inflammatory dermatologic disease.

Authors:  Ricardo T Paniagua; David F Fiorentino; Lorinda Chung; William H Robinson
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

Review 2.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 3.  Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children.

Authors:  Musturay Karcaaltincaba; Berna Oguz; Mithat Haliloglu
Journal:  Pediatr Radiol       Date:  2009-06

Review 4.  Renal effects of targeted anticancer therapies.

Authors:  Camillo Porta; Laura Cosmai; Maurizio Gallieni; Paolo Pedrazzoli; Fabio Malberti
Journal:  Nat Rev Nephrol       Date:  2015-03-03       Impact factor: 28.314

5.  Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Miguel L Graciano; Kenneth D Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-05

6.  Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.

Authors:  Mohamed E Shaker; Khaled R Zalata; Wajahat Z Mehal; Gamal E Shiha; Tarek M Ibrahim
Journal:  Toxicol Appl Pharmacol       Date:  2011-02-24       Impact factor: 4.219

Review 7.  Current themes in molecular pediatrics: molecular medicine and its applications.

Authors:  Andrea Superti-Furga; Livia Garavelli
Journal:  Ital J Pediatr       Date:  2010-02-19       Impact factor: 2.638

8.  [Nephrogenic systemic fibrosis: a rare disease with grave consequences].

Authors:  J T Kielstein; M Schiffer
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

Review 9.  Cutaneous manifestations of ESRD.

Authors:  Timur A Galperin; Antonia J Cronin; Kieron S Leslie
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

10.  Nephrogenic systemic fibrosis.

Authors:  Bhushan Madke; Uday Khopkar
Journal:  Indian Dermatol Online J       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.